Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen

BACKGROUND: Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). Cetuximab manufactured by ImClone (US commercial cetuximab) potentially results in higher...

Descripción completa

Detalles Bibliográficos
Autores principales: Soulières, Denis, Aguilar, Jose Luis, Chen, Eric, Misiukiewicz, Krzysztof, Ernst, Scott, Lee, Hyun Jung, Bryant, Katherine, He, Shuang, Obasaju, Coleman K., Chang, Shao-Chun, Chin, Steve, Adkins, Douglas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714495/
https://www.ncbi.nlm.nih.gov/pubmed/26768732
http://dx.doi.org/10.1186/s12885-016-2064-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714495/
https://www.ncbi.nlm.nih.gov/pubmed/26768732
http://dx.doi.org/10.1186/s12885-016-2064-0

Ejemplares similares